Literature DB >> 21421873

Test-retest variability of reading performance metrics using MNREAD in patients with age-related macular degeneration.

Praveen J Patel1, Fred K Chen, Lyndon Da Cruz, Gary S Rubin, Adnan Tufail.   

Abstract

PURPOSE: To determine the test-retest variability of reading ability using the MNREAD charts in patients with stable age-related macular degeneration (AMD).
METHODS: In this prospective study, reading ability was measured at two visits in 124 nontreated eyes of 124 patients with AMD, who were enrolled in an ongoing clinical trial using a standardized MNREAD protocol. Only patients with stable AMD who could perform the reading test at 40 cm at both visits were included in the analysis. Different scoring rules were applied to calculate critical print size and maximum reading speed.
RESULTS: Data from the 59 patients with a mean (SD) age of 78 (7.6) years who met the study criteria were analyzed at a mean (SD) interval of 43 (6) days between measurements. The 95% coefficient of repeatability (CR) was 0.30 logMAR for reading acuity. The CR for critical print size and maximum reading speed varied depending on the analysis method applied.
CONCLUSIONS: This is a report of estimates of the intersession test-retest variability of reading performance metrics in patients with stable AMD. The results are helpful both in defining end points in clinical trials for AMD and in distinguishing clinical change from measurement variability in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21421873     DOI: 10.1167/iovs.10-6601

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  18 in total

1.  Repeatability of visual function measures in age-related macular degeneration.

Authors:  Tariq Aslam; Sajjad Mahmood; Konstantinos Balaskas; Niall Patton; Rajeev G Tanawade; Shi Zhuan Tan; Stephen A Roberts; Jeremy Parkes; Paul N Bishop
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-07-25       Impact factor: 3.117

2.  Reading Ability among Patients Presenting for Ophthalmic and Nonophthalmic Surgery.

Authors:  Regina A de Luna; Angeline M Nguyen; Pradeep Y Ramulu
Journal:  Ophthalmology       Date:  2017-01-26       Impact factor: 12.079

3.  Development of a Reading Accessibility Index Using the MNREAD Acuity Chart.

Authors:  Aurélie Calabrèse; Cynthia Owsley; Gerald McGwin; Gordon E Legge
Journal:  JAMA Ophthalmol       Date:  2016-04       Impact factor: 7.389

4.  Comparison of Reading Test Parameters from the Print and Tablet Application Forms of the Minnesota Low Vision Reading Test.

Authors:  Deniz Altınbay; Esra Şahlı; Şefay Aysun İdil
Journal:  Turk J Ophthalmol       Date:  2022-06-29

5.  Development and Validation of the Persian Version of the MNREAD Acuity Chart.

Authors:  Roghiyeh Elham; Ebrahim Jafarzadepur
Journal:  J Curr Ophthalmol       Date:  2020-07-04

Review 6.  CLINICAL ENDPOINTS FOR THE STUDY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.

Authors:  SriniVas R Sadda; Usha Chakravarthy; David G Birch; Giovanni Staurenghi; Erin C Henry; Christopher Brittain
Journal:  Retina       Date:  2016-10       Impact factor: 4.256

7.  The Evaluation of Reading Performance with Minnesota Low Vision Reading Charts in Patients with Age-related Macular Degeneration.

Authors:  Deniz Altinbay; Fatih Mehmet Adibelli; Ibrahim Taskin; Adil Tekin
Journal:  Middle East Afr J Ophthalmol       Date:  2016 Oct-Dec

Review 8.  Reading charts in ophthalmology.

Authors:  W Radner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-14       Impact factor: 3.117

9.  Comparing performance on the MNREAD iPad application with the MNREAD acuity chart.

Authors:  Aurélie Calabrèse; Long To; Yingchen He; Elizabeth Berkholtz; Paymon Rafian; Gordon E Legge
Journal:  J Vis       Date:  2018-01-01       Impact factor: 2.240

10.  Enhanced text spacing improves reading performance in individuals with macular disease.

Authors:  Sally Blackmore-Wright; Mark A Georgeson; Stephen J Anderson
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.